GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial for SPD8, a Denosumab biosimilar co-developed with Mitsubishi Gas Chemical, has successfully met its primary endpoint. Statistical...